Immunologic Research

, Volume 66, Issue 2, pp 299–304 | Cite as

Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity

  • Zhao-wei Gao
  • Guan-hua Zhao
  • Zhe Zhang
  • Jing Huang
  • Zi-yue Li
  • Hui-zhong ZhangEmail author
  • Ke DongEmail author
Original Article


Adenosine deaminase (ADA) has been found to be involved in autoimmune disease progression. To assess the potential application of serum ADA activity in diagnosing systemic lupus erythematosus (SLE) and evaluating SLE disease activity, we investigated the serum ADA activity of 120 SLE patients and 120 healthy controls in the present study. The results showed that serum ADA activity in SLE patients was significantly increased (median (IQR) = 14 (11–19) U/L) compared with that in healthy controls (median (IQR) = 8 (7–10) U/L). Based on a receiver operating characteristic curve analysis, the optimal cut-off value for using serum ADA activity to diagnose SLE patients was 10.5 U/L (specificity, 84.2%; sensitivity, 78.3%). The diagnostic performance of serum ADA activity for SLE patients was better than that of other conventional haematology markers. Moreover, serum ADA activity displayed an increasing trend with increasing SLE disease activity. Spearman’s correlation analysis showed that serum ADA activity was positively correlated with SLE disease activity. These findings suggest that serum ADA activity could be a diagnostic marker for SLE; moreover, measuring serum ADA activity may be helpful for evaluating and monitoring the disease activity of SLE patients.


SLE ADA Diagnosis Disease activity 



This study was supported by the National Natural Science Foundation of China (no. 81572974).

Compliance with ethical standards

This project was approved by the Ethics Committee of the Tangdu Hospital, Fourth Military Medical University. Ethical approval was obtained from the Ethics Committee of Tangdu Hospital, Fourth Military Medical University (TDLL-20151209), and informed consent was not required.

Conflict of interests

The authors declare that they have no conflict of interest.

Supplementary material

12026_2018_8984_MOESM1_ESM.xlsx (20 kb)
ESM 1 (XLSX 20 kb)


  1. 1.
    Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9. Scholar
  2. 2.
    Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70. Scholar
  3. 3.
    Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev. 1998;161(1):27–42. Scholar
  4. 4.
    Whitmore KV, Gaspar HB. Adenosine deaminase deficiency—more than just an immunodeficiency. Front Immunol. 2016;7:314. Scholar
  5. 5.
    Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38.
  6. 6.
    Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. 2016;128(1):45–54.
  7. 7.
    Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2010;10(6):551–6. Scholar
  8. 8.
    Sauer AV, Morbach H, Brigida I, Ng YS, Aiuti A, Meffre E. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Investig. 2012a;122(6):2141–52. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012b;119(6):1428–39. Scholar
  10. 10.
    Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol. 2012c;3:265. Scholar
  11. 11.
    Vinapamula KS, Pemmaraju SV, Bhattaram SK, Bitla AR, Manohar SM. Serum adenosine deaminase as inflammatory marker in rheumatoid arthritis. J Clin Diagn Res: JCDR. 2015;9(9):Bc08–10. Scholar
  12. 12.
    Xun C, Zhao Y, Hu ZJ. Potential role of adenosine deaminase in the diagnosis of adult-onset Still’s disease. Rheumatol Int. 2013;33(5):1255–8. Scholar
  13. 13.
    Taysi S, Polat MF, Sari RA, Bakan E. Serum adenosine deaminase and cytidine deaminase activities in patients with systemic lupus erythematosus. Clin Chem Lab Med. 2002;40(5):493–5. CrossRefPubMedGoogle Scholar
  14. 14.
    Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Medicinski Glasnik: Off Publ Med Assoc Zenica-Doboj Canton, Bosnia and Herzegovina. 2011;8(1):163–8.Google Scholar
  15. 15.
    Saghiri R, Ghashghai N, Movaseghi S, Poursharifi P, Jalilfar S, Bidhendi MA, et al. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int. 2012;32(6):1633–8. Scholar
  16. 16.
    Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2001;20(6):411–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Demir G, Borman P, Ayhan F, Ozgun T, Kaygisiz F, Yilmez G. Serum adenosine deaminase level is high but not related with disease activity parameters in patients with rheumatoid arthritis. Open Rheumatol J. 2014;8(1):24–8. Scholar
  18. 18.
    Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32(7):1967–75. Scholar
  19. 19.
    Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2015;14(5):423–31. Scholar
  20. 20.
    Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. Scholar
  21. 21.
    Mak A, Kow NY. Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int. 2014;2014:178721–11. Scholar
  22. 22.
    van den Berg L, Nossent H, Rekvig O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol. 2006;25(3):347–52. CrossRefPubMedGoogle Scholar
  23. 23.
    Chung L, Flyckt RL, Colon I, Shah AA, Druzin M, Chakravarty EF. Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus. 2006;15(9):595–9. Scholar
  24. 24.
    Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;13(1):36–44. Scholar
  25. 25.
    Jolly M, Smaron M, Olsen Utset T, Ellman M. Are isolated antinucleolar antibodies a marker of scleroderma? J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2003;9(5):291–5. Scholar
  26. 26.
    van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods. 1991;140(2):181–9. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical DiagnosisTangdu Hospital, Fourth Military Medical UniversityXi’anChina

Personalised recommendations